The Graveyard of Solutions That Work

A cheap generic drug reduces a common complication by 40% in a mid-size clinical trial. The results are solid. The methodology is clean. The drug costs pennies per dose.

Nobody funds the follow-up study. Not because the science is weak, but because there is no patent to extend, no exclusive license to sell, no billion-dollar market to capture. The discovery sits in a journal archive, cited six times in twelve years.

This is the graveyard of solutions that work: research that produces genuine value but lacks a commercial constituency.

The pattern repeats across fields. An agricultural technique that reduces water use by 30% but relies on freely available seeds. A diagnostic method that costs one-tenth of the standard test but uses off-patent reagents. A soil remediation approach that works better than commercial alternatives but cannot be trademarked.

The market does not fund what it cannot own. And institutional science increasingly follows market logic.

Grant committees ask about commercialization potential. Universities measure technology transfer revenue. Researchers learn to frame discoveries in terms of market opportunity rather than public benefit. The result: effective solutions without profit margins join the file drawer, while expensive marginal improvements get funded repeatedly.

The question is not whether commercialization matters. It does. The question is whether a system that only values what can be sold is capable of producing the full range of knowledge humanity needs.

Some of the most important research of the next decade will produce solutions that save money rather than make it. Methods that reduce costs, simplify processes, or use freely available materials. These contributions are economically valuable to society but economically invisible to the current funding apparatus.

A model built around science crowdfunding offers one path forward — funding that comes from people who benefit from solutions rather than from entities that need to own them. When the beneficiaries of research are ordinary people, ordinary people can be the ones who sustain it.

Discussion question: What is the most impactful piece of research you know of that was abandoned not because it failed, but because it succeeded too cheaply?